

Gavin P Reynolds

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1929325/gavin-p-reynolds-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

333
papers

17,958
citations

73
h-index

124
g-index

358
ext. papers

19,075
ext. citations

6.6
avg, IF

6.57
L-index

#	Paper	IF	Citations
333	Subchronic PCP effects on DNA methylation and protein expression of NMDA receptor subunit genes in the prefrontal cortex and hippocampus of female rats.. <i>Journal of Psychopharmacology</i> , 2022 , 2698811211069109	4.6	0
332	Changes of exon IV DNA methylation are associated with methamphetamine dependence. <i>Epigenomics</i> , 2021 , 13, 953-965	4.4	2
331	The relationship of childhood trauma and DNA methylation of NMDA receptor genes in first-episode schizophrenia. <i>Epigenomics</i> , 2021 , 13, 927-937	4.4	2
330	The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and Environment. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 854-855	5.8	1
329	Early-life stress effects on BDNF DNA methylation in first-episode psychosis and in rats reared in isolation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 108, 110188	5.5	6
328	Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 253-255	5.8	1
327	High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?. <i>Journal of Psychopharmacology</i> , 2021 , 35, 1030-1036	4.6	1
326	The neurochemical pathology of schizophrenia: post-mortem studies from dopamine to parvalbumin.. <i>Journal of Neural Transmission</i> , 2021 , 1	4.3	2
325	methylation: association with cortisol, perceived stress, rs1006737 and childhood trauma in males. <i>Epigenomics</i> , 2020 , 12, 1739-1749	4.4	1
324	Antipsychotics, Weight Gain and Metabolic Risk 2020 , 619-619		
323	M9. RATS REARED IN SOCIAL ISOLATION INDUCES EPIGENETIC MODIFICATIONS IN THE NMDA RECEPTOR SUBUNITS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S136-S136	1.3	78
322	Functional pharmacogenetics of serotonin receptors in psychiatric drug action. <i>Handbook of Behavioral Neuroscience</i> , 2020 , 31, 941-957	0.7	2
321	Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	13
320	M210. GRIN2B METHYLATION IS RELATED TO PANSS EXCITED COMPONENT (PANSS-EC) IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020 , 46, S216-S216	1.3	78
319	Uric Acid and High-Density Lipoprotein Cholesterol Are Differently Associated with Alzheimer's Disease and Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 1125-1131	4.3	4
318	Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020 , 127, 779-783	4.3	2
317	S8. GRIN1 PROMOTER METHYLATION CHANGES IN BLOOD OF EARLY-ONSET PSYCHOTIC PATIENTS AND UNAFFECTED SIBLINGS WITH CHILDHOOD TRAUMA. <i>Schizophrenia Bulletin</i> , 2020 , 46, S32-S33	1.3	78

316	Circulating microRNA changes in patients with impaired glucose regulation. <i>Adipocyte</i> , 2020 , 9, 443-453	3.2	3
315	Epigenetic-mediated -methyl-D-aspartate receptor changes in the brain of isolated reared rats. <i>Epigenomics</i> , 2020 , 12, 1983-1997	4.4	3
314	Interaction Between Variations in Dopamine D2 and Serotonin 2A Receptor is Associated with Short-Term Response to Antipsychotics in Schizophrenia. <i>Neuroscience Bulletin</i> , 2019 , 35, 1102-1105	4.3	1
313	Neuromyelitis optica spectrum disorder in three generations of a Chinese family. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 32, 94-96	4	1
312	Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019 , 17, 314-317	3.4	4
311	Association of SLC1A2 and SLC17A7 polymorphisms with major depressive disorder in a Thai population. <i>Asian Biomedicine</i> , 2019 , 12, 131-138	0.4	0
310	GRIN2B promoter methylation deficits in early-onset schizophrenia and its association with cognitive function. <i>Epigenomics</i> , 2019 , 11, 401-410	4.4	24
309	Parvalbumin Promoter Methylation Altered in Major Depressive Disorder. <i>International Journal of Medical Sciences</i> , 2019 , 16, 1207-1214	3.7	5
308	Association study of the functional Catechol-O-Methyltransferase (COMT) ValMet polymorphism on executive cognitive function in a Thai sample. <i>International Journal of Medical Sciences</i> , 2019 , 16, 1461-1465	2.7	2
307	Lower uric acid is associated with poor short-term outcome and a higher frequency of posterior arterial involvement in ischemic stroke. <i>Neurological Sciences</i> , 2018 , 39, 1117-1119	3.5	8
306	Parvalbumin promoter hypermethylation in postmortem brain in schizophrenia. <i>Epigenomics</i> , 2018 , 10, 519-524	4.4	20
305	Genetic variation of GRIA3 gene is associated with vulnerability to methamphetamine dependence and its associated psychosis. <i>Journal of Psychopharmacology</i> , 2018 , 32, 309-315	4.6	7
304	S14. DNA METHYLATION CHANGES IN GABAERGIC AND GLUTAMATERGIC MARKERS IN EARLY SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018 , 44, S329-S329	1.3	0
303	Development and evaluation of a dimensionless mechanistic pan coating model for the prediction of coated tablet appearance. <i>International Journal of Pharmaceutics</i> , 2017 , 528, 180-201	6.5	18
302	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. <i>Therapeutic Advances in Psychopharmacology</i> , 2017 , 7, 1-14	4.9	14
301	Association of polymorphisms in GAD1 and GAD2 genes with methamphetamine dependence. <i>Pharmacogenomics</i> , 2017 , 18, 17-22	2.6	6
300	Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. <i>Journal of Psychopharmacology</i> , 2017 , 31, 1430-1436	4.6	38
299	Increased DNA methylation in the parvalbumin gene promoter is associated with methamphetamine dependence. <i>Pharmacogenomics</i> , 2017 , 18, 1317-1322	2.6	9

298	DAT1 methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 291-299	3.8	34
297	Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain. <i>Epigenomics</i> , 2016 , 8, 1179-83	4.4	19
296	TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs. <i>International Journal of Neuropsychopharmacology</i> , 2016 , 19,	5.8	18
295	Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. <i>Journal of Psychopharmacology</i> , 2016 , 30, 1141-1144	4.6	22
294	Association of brain-derived neurotrophic factor valine to methionine polymorphism with sexual dysfunction following selective serotonin reuptake inhibitor treatment in female patients with major depressive disorder. <i>Asia-Pacific Psychiatry</i> , 2016 , 8, 260-268	3.2	
293	Does elevated peripheral benzodiazepine receptor gene expression relate to cognitive deficits in methamphetamine dependence?. <i>Human Psychopharmacology</i> , 2016 , 31, 243-6	2.3	2
292	Blood oxygen level-dependent signals via fMRI in the mood-regulating circuit using two animal models of depression are reversed by chronic escitalopram treatment. <i>Behavioural Brain Research</i> , 2016 , 311, 210-218	3.4	15
291	Effect of Methamphetamine Exposure on Expression of Calcium Binding Proteins in Rat Frontal Cortex and Hippocampus. <i>Neurotoxicity Research</i> , 2016 , 30, 427-33	4.3	10
290	BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. <i>Journal of Psychopharmacology</i> , 2016 , 30, 717-48	4.6	127
289	Concurrent Risperidone Administration Attenuates the Development of Locomotor Sensitization Following Sub-Chronic Phencyclidine in Rats. <i>Pharmacopsychiatry</i> , 2016 , 49, 62-5	2	2
288	BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence. <i>Pharmacogenomics</i> , 2015 , 16, 1541-5	2.6	23
287	Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 654-72	3.8	30
286	Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action. <i>Pharmacogenomics</i> , 2014 , 15, 1599-609	2.6	9
285	Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. <i>Pharmacogenomics</i> , 2014 , 15, 477-85	2.6	29
284	Genetic association of LMAN2L gene in schizophrenia and bipolar disorder and its interaction with ANK3 gene polymorphism. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 54, 157-62	5.5	16
283	Analysis of sociability and preference for social novelty in the acute and subchronic phencyclidine rat. <i>Journal of Psychopharmacology</i> , 2014 , 28, 955-63	4.6	13
282	Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 485-90	5.8	16
281	Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 645-9	5.8	39

280	Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. <i>Human Psychopharmacology</i> , 2014 , 29, 38-45	2.3	9
279	SMARTS (Systematic Monitoring of Adverse events Related to Treatments): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. <i>Therapeutic Advances in Psychopharmacology</i> , 2014 , 4, 15-21	4.9	22
278	Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. <i>Pharmacogenomics</i> , 2013 , 14, 505-14	2.6	15
277	Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. <i>Pharmacogenomics</i> , 2013 , 14, 277-88	2.6	38
276	Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population. <i>Neuroscience Letters</i> , 2013 , 551, 58-61	3.3	19
275	The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 1421-5	5.8	22
274	The pharmacogenetics of antipsychotic treatment. <i>Handbook of Experimental Pharmacology</i> , 2012 , 213-392	3.9	5
273	An association between genotypic variations and protein expression of the glial glutamate transporter 2 in the human nucleus accumbens. <i>Neuroscience Letters</i> , 2012 , 523, 108-10	3.3	2
272	Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration. <i>BMC Medical Genetics</i> , 2012 , 13, 91	2.1	8
271	The effect of chronic antipsychotic drug on hypothalamic expression of neural nitric oxide synthase and dopamine D2 receptor in the male rat. <i>PLoS ONE</i> , 2012 , 7, e33247	3.7	4
270	Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. <i>Journal of Psychopharmacology</i> , 2012 , 26, 349-59	4.6	51
269	Histamine and antipsychotic drug-induced weight gain. <i>Journal of Psychopharmacology</i> , 2012 , 26, 1608-94.6	4.6	4
268	The pharmacogenetics of symptom response to antipsychotic drugs. <i>Psychiatry Investigation</i> , 2012 , 9, 1-7	3.1	26
267	Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012 , 10, 71-7	3.4	43
266	Hippocampal neurochemistry is involved in the behavioural effects of neonatal maternal separation and their reversal by post-weaning environmental enrichment: a magnetic resonance study. <i>Behavioural Brain Research</i> , 2011 , 217, 122-7	3.4	67
265	Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. <i>Pharmacogenomics</i> , 2011 , 12, 727-34	2.6	23
264	Learning and memory alterations are associated with hippocampal N-acetylaspartate in a rat model of depression as measured by 1H-MRS. <i>PLoS ONE</i> , 2011 , 6, e28686	3.7	43
263	The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat. <i>Journal of Sexual Medicine</i> , 2011 , 8, 3345-53	1.1	11

262	Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011 , 45, 54-9	5.2	38
261	Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine. <i>Therapeutic Advances in Psychopharmacology</i> , 2011 , 1, 197-204	4.9	28
260	Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. <i>Pharmacogenomics</i> , 2011 , 12, 1127-36	2.6	43
259	Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. <i>European Journal of Neuroscience</i> , 2010 , 31, 349-58	3.5	66
258	The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. <i>Journal of Psychopharmacology</i> , 2010 , 24, 1-8	4.6	10
257	Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse. <i>Human Molecular Genetics</i> , 2010 , 19, 3402-12	5.6	11
256	Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. <i>Neuroscience Letters</i> , 2010 , 471, 144-7	3.3	46
255	Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. <i>Behavioural Brain Research</i> , 2010 , 208, 132-6	3.4	38
254	Tryptophan depletion impairs object-recognition memory in the rat: reversal by risperidone. <i>Behavioural Brain Research</i> , 2010 , 208, 479-83	3.4	28
253	The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues. <i>European Neuropsychopharmacology</i> , 2010 , 20, 211-7	1.2	7
252	Adolescent escitalopram administration modifies neurochemical alterations in the hippocampus of maternally separated rats. <i>European Neuropsychopharmacology</i> , 2010 , 20, 875-83	1.2	20
251	Functional Pharmacogenetics of Serotonin Receptors in Psychiatric Drug Action. <i>Handbook of Behavioral Neuroscience</i> , 2010 , 791-806	0.7	2
250	Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. <i>Pharmacology & Therapeutics</i> , 2010 , 125, 169-79	13.9	276
249	Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. <i>Journal of Affective Disorders</i> , 2010 , 123, 308-11	6.6	42
248	Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. <i>Psychopharmacology</i> , 2009 , 207, 119-25	4.7	67
247	Single drop behaviour in a high shear granulator. <i>Powder Technology</i> , 2009 , 189, 357-364	5.2	15
246	Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat. <i>Behavioural Brain Research</i> , 2009 , 205, 355-9	3.4	50
245	Effect of acute tryptophan depletion on noradrenaline and dopamine in the rat brain. <i>Journal of Psychopharmacology</i> , 2009 , 23, 51-5	4.6	31

244	The neurochemistry of schizophrenia. <i>Psychiatry (Abingdon, England)</i> , 2008 , 7, 425-429		6
243	Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. <i>Behavioural Brain Research</i> , 2008 , 194, 230-5	3.4	42
242	Acute tryptophan depletion does not alter central or plasma brain-derived neurotrophic factor in the rat. <i>European Neuropsychopharmacology</i> , 2008 , 18, 317-22	1.2	9
241	Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. <i>Journal of Psychopharmacology</i> , 2008 , 22, 567-71	4.6	26
240	Influence of 5-HT _{2C} receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. <i>British Journal of Psychiatry</i> , 2008 , 192, 424-8	5.4	75
239	Sub-chronic phencyclidine administration increases brain-derived neurotrophic factor in the RAT hippocampus. <i>Schizophrenia Research</i> , 2007 , 94, 371-2	3.6	7
238	5-HT _{2C} receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. <i>Brain Research</i> , 2007 , 1149, 14-7	3.7	47
237	The impact of pharmacogenetics on the development and use of antipsychotic drugs. <i>Drug Discovery Today</i> , 2007 , 12, 953-9	8.8	32
236	Acute and chronic tryptophan depletion differentially regulate central 5-HT _{1A} and 5-HT _{2A} receptor binding in the rat. <i>Psychopharmacology</i> , 2007 , 190, 497-506	4.7	67
235	Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. <i>Journal of Neural Transmission</i> , 2007 , 114, 893-8	4.3	120
234	Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. <i>Journal of Psychopharmacology</i> , 2007 , 21, 198-205	4.6	171
233	The neuronal pathology of schizophrenia: molecules and mechanisms. <i>Biochemical Society Transactions</i> , 2007 , 35, 433-6	5.1	33
232	The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat. <i>Journal of Psychopharmacology</i> , 2007 , 21, 428-34	4.6	10
231	Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. <i>Journal of Neural Transmission Supplementum</i> , 2007 , 281-5		36
230	Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. <i>Journal of Psychopharmacology</i> , 2006 , 20, 577-9	4.6	24
229	Selective increases in the cytokine, TNF α , in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. <i>Journal of Psychopharmacology</i> , 2006 , 20, 636-42	4.6	27
228	Pharmacogenetics of schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1429-40	4	13
227	The 5-HT _{2C} receptor and antipsychotic-induced weight gain - mechanisms and genetics. <i>Journal of Psychopharmacology</i> , 2006 , 20, 15-8	4.6	123

226	The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. <i>Behavioural Brain Research</i> , 2006 , 169, 263-73	3.4	122
225	Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. <i>American Journal of Psychiatry</i> , 2006 , 163, 1826-9	11.9	89
224	Metabolic syndrome and schizophrenia. <i>British Journal of Psychiatry</i> , 2006 , 188, 86; author reply 86-7	5.4	8
223	Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. <i>Journal of Neural Transmission Supplementum</i> , 2006 , 39-43		31
222	Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. <i>European Neuropsychopharmacology</i> , 2005 , 15, 143-51	1.2	108
221	An in vitro model of inflammatory neurodegeneration and its neuroprotection. <i>Neuroscience Letters</i> , 2005 , 388, 39-44	3.3	16
220	The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005 , 29, 1021-8	5.5	112
219	Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. <i>Schizophrenia Research</i> , 2005 , 73, 147-52	3.6	44
218	Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. <i>Schizophrenia Research</i> , 2005 , 75, 303-8	3.6	46
217	Chronic haloperidol or clozapine treatment does not alter parvalbumin immunoreactivity in the rat frontal cortex or hippocampus. <i>Neuroscience Letters</i> , 2005 , 373, 57-60	3.3	10
216	Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 195-200	1.9	215
215	The neurochemistry of schizophrenia. <i>Psychiatry (Abingdon, England)</i> , 2005 , 4, 21-25		2
214	Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol. <i>Journal of Psychopharmacology</i> , 2005 , 19, 597-601	4.6	23
213	Receptor mechanisms in the treatment of schizophrenia. <i>Journal of Psychopharmacology</i> , 2004 , 18, 340-5	4.6	88
212	Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. <i>British Journal of Psychiatry</i> , 2004 , 184, 58-62	5.4	168
211	Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. <i>European Journal of Pharmacology</i> , 2004 , 505, 253-4	5.3	30
210	Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models. <i>Neurotoxicity Research</i> , 2004 , 6, 57-61	4.3	125
209	Reduced N-acetylaspartate in the temporal cortex of rats reared in isolation. <i>Biological Psychiatry</i> , 2004 , 56, 296-9	7.9	28

208	Region specific changes in forebrain 5-hydroxytryptamine1A and 5-hydroxytryptamine2A receptors in isolation-reared rats: an in vitro autoradiography study. <i>Neuroscience</i> , 2004 , 123, 725-32	3.9	76
207	The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. <i>Neuroscience Letters</i> , 2004 , 372, 173-7	3.3	111
206	What's new in □The neurochemistry of schizophrenia. <i>Medicine</i> , 2004 , 32, 1-4	0.6	
205	Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. <i>Psychiatric Genetics</i> , 2003 , 13, 187-92	2.9	43
204	N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. <i>Biological Psychiatry</i> , 2003 , 53, 1138-41	7.9	52
203	Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats. <i>Neuroscience</i> , 2003 , 119, 233-40	3.9	69
202	Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. <i>American Journal of Psychiatry</i> , 2003 , 160, 677-9	11.9	172
201	The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. <i>Journal of Psychopharmacology</i> , 2003 , 17, 57-65	4.6	94
200	The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. <i>Journal of Psychiatric Research</i> , 2002 , 36, 317-24	5.2	55
199	Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. <i>Journal of Neural Transmission</i> , 2002 , 109, 881-9	4.3	70
198	The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. <i>Journal of Neurochemistry</i> , 2002 , 81, 46-59	6	90
197	Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. <i>Molecular Psychiatry</i> , 2002 , 7, 670-1	15.1	62
196	The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. <i>Journal of Psychopharmacology</i> , 2002 , 16, 35-7	4.6	45
195	Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. <i>Biological Psychiatry</i> , 2002 , 52, 708-15	7.9	298
194	A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. <i>Schizophrenia Research</i> , 2002 , 55, 1-10	3.6	361
193	Neuronal calcium-binding proteins and schizophrenia. <i>Schizophrenia Research</i> , 2002 , 57, 27-34	3.6	98
192	Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. <i>Lancet, The</i> , 2002 , 359, 2086-7	4.0	346
191	A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. <i>Chinese Medical Journal</i> , 2002 , 115, 819-23	2.9	28

190	Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex. <i>Journal of Psychiatric Research</i> , 2001 , 35, 23-8	5.2	18
189	Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. <i>Brain Research Bulletin</i> , 2001 , 55, 579-84	3.9	124
188	Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophrenia. <i>Neuroscience Letters</i> , 2001 , 304, 9-12	3.3	36
187	Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. <i>Neuroscience Letters</i> , 2001 , 309, 193-6	3.3	31
186	GABAergic neuronal subtypes in the human frontal cortex--development and deficits in schizophrenia. <i>Journal of Chemical Neuroanatomy</i> , 2001 , 22, 95-100	3.2	122
185	Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 543-8	4	5
184	Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia. <i>Acta Pharmacologica Sinica</i> , 2001 , 22, 76-80	8	0
183	The new antipsychotics--some pharmacological aspects of their problems and potential. <i>Expert Opinion on Pharmacotherapy</i> , 2000 , 1, 181-5	4	4
182	Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. <i>Journal of Neurochemistry</i> , 1999 , 72, 1773-6	6	72
181	Neurochemistry of Human Postmortem Brain 1999 , 319-346		
180	Dopamine receptors, antipsychotic action and schizophrenia. <i>Journal of Psychopharmacology</i> , 1999 , 13, 202-3	4.6	1
179	Effects of excitotoxic lesions of the rat prefrontal cortex on CREB regulation and presynaptic markers of dopamine and amino acid function in the nucleus accumbens. <i>European Journal of Neuroscience</i> , 1999 , 11, 1265-74	3.5	29
178	Agonist-stimulated GTPgamma[35S] binding to 5-HT(1A) receptors in human post-mortem brain. <i>European Journal of Pharmacology</i> , 1999 , 386, 313-5	5.3	20
177	Deficits of NMDA receptors and glutamate uptake sites in the frontal cortex in AIDS. <i>NeuroReport</i> , 1999 , 10, 3513-5	1.7	26
176	Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. <i>Neuroscience Letters</i> , 1998 , 241, 53-6	3.3	84
175	Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. <i>Neuroscience Letters</i> , 1998 , 241, 143-6	3.3	40
174	Developments in antipsychotic drugs - an update. <i>Expert Opinion on Investigational Drugs</i> , 1998 , 7, 257-60	6.9	2
173	Receptor mechanisms of antipsychotic drug atypicality. <i>European Psychiatry</i> , 1998 , 13, 5s-8s	6	1

172	Antipsychotic drug affinities at alpha2-adrenoceptor subtypes in post-mortem human brain. <i>Journal of Psychopharmacology</i> , 1998 , 12, 151-4	4.6	17
171	Pocket Handbook of Psychiatric Drug Treatment, 2nd ed.. <i>American Journal of Psychiatry</i> , 1998 , 155, 1621-1621	11.6	218
170	What is an atypical antipsychotic?. <i>Journal of Psychopharmacology</i> , 1997 , 11, 195-9	4.6	29
169	5-HT receptors, genes and antipsychotic mechanisms. <i>Journal of Psychopharmacology</i> , 1997 , 11, 26-7	4.6	5
168	Schizophrenia - advances in drug therapy. <i>Expert Opinion on Investigational Drugs</i> , 1997 , 6, 857-66	5.9	2
167	Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. <i>Schizophrenia Research</i> , 1997 , 24, 349-55	3.6	303
166	S.17.03 Antipsychotic drugs and neurotransmitter receptor regulation. <i>European Neuropsychopharmacology</i> , 1997 , 7, S110-S111	1.2	
165	Deficits of [3H]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. <i>Neuroscience Letters</i> , 1997 , 232, 13-6	3.3	30
164	Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders. <i>Behavioural Brain Research</i> , 1996 , 73, 249-52	3.4	55
163	Imidazoline binding sites in Huntington's and Parkinson's disease putamen. <i>European Journal of Pharmacology</i> , 1996 , 301, R19-21	5.3	39
162	An improved model for examining delayed excitotoxic neurodegeneration in isolated chick retina. <i>Neuroscience Letters</i> , 1996 , 219, 65-7	3.3	1
161	The importance of dopamine D4 receptors in the action and development of antipsychotic agents. <i>Drugs</i> , 1996 , 51, 7-11	12.1	39
160	Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. <i>NeuroReport</i> , 1996 , 7, 910-2	1.7	103
159	5-Hydroxytryptamine deficits in the caudate nucleus in AIDS. <i>Aids</i> , 1996 , 10, 1303-4	3.5	7
158	Dopamine receptors and schizophrenia. <i>Biochemical Society Transactions</i> , 1996 , 24, 202-205	5.1	8
157	Dopamine D4 receptors in schizophrenia?. <i>Journal of Neurochemistry</i> , 1996 , 66, 881-3	6	10
156	Dopamine receptors and schizophrenia. <i>Biochemical Society Transactions</i> , 1996 , 24, 202-5	5.1	2
155	Muscarinic M1 receptors in schizophrenia. <i>Molecular Psychiatry</i> , 1996 , 1, 364-6	15.1	2

154	Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1-positive patients. <i>Journal of Neurochemistry</i> , 1995 , 64, 932-5	6	73
153	An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. <i>Journal of Neural Transmission</i> , 1995 , 102, 67-73	4.3	13
152	Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research. Report from the European Dementia and Schizophrenia Network (BIOMED I). <i>Journal of Neural Transmission</i> , 1995 , 102, 255-64	4.3	13
151	Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. <i>Journal of Psychiatric Research</i> , 1995 , 29, 227-32	5.2	117
150	Clozapine-induced hypersalivation and the alpha 2 adrenoceptor. <i>British Journal of Psychiatry</i> , 1995 , 167, 412	5.4	70
149	New approaches to the drug treatment of schizophrenia. <i>Advances in Pharmacology</i> , 1995 , 32, 461-503	5.7	17
148	Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. <i>European Journal of Pharmacology</i> , 1995 , 281, R5-6	5.3	67
147	Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. <i>Neuroscience Letters</i> , 1995 , 187, 9-12	3.3	64
146	5-Hydroxytryptamine (5-HT) ₄ receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. <i>British Journal of Pharmacology</i> , 1995 , 114, 993-8	8.6	148
145	Neurotransmitter systems in schizophrenia. <i>International Review of Neurobiology</i> , 1995 , 38, 305-39	4.4	12
144	Are striatal dopamine D4 receptors increased in schizophrenia?. <i>Journal of Neurochemistry</i> , 1994 , 63, 1576-7	6	73
143	Neocortical neurotransmitter markers in Huntington's disease. <i>Journal of Neural Transmission</i> , 1994 , 98, 197-207	4.3	8
142	Differential regulation of cardiac alpha- and beta-adrenoceptors by the sympathetic nervous system. <i>Autonomic and Autacoid Pharmacology</i> , 1994 , 14, 29-36		3
141	Deficit of [3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease. <i>Journal of the Neurological Sciences</i> , 1994 , 125, 46-9	3.2	11
140	Glutamate in Huntington's disease. <i>Lancet, The</i> , 1994 , 344, 189-90	4.0	12
139	Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1994 , 380, 36-40	6.5	21
138	Arachidonic acid: a common link in the biology of schizophrenia?. <i>Archives of General Psychiatry</i> , 1994 , 51, 665-6		49
137	Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro. <i>European Journal of Pharmacology</i> , 1993 , 242, 183-7	5.3	16

136	Free radical damage in Down's syndrome brain. <i>Biochemical Society Transactions</i> , 1993 , 21, 221S	5.1	16
135	Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. <i>International Clinical Psychopharmacology</i> , 1993 , 8, 151-3	2.2	79
134	Hippocampal tin, aluminum and zinc in Alzheimer's disease. <i>BioMetals</i> , 1993 , 6, 149-54	3.4	95
133	D-aspartate binding to the glutamate uptake site in human brain tissue--effects of leucotomy. <i>Journal of Neural Transmission</i> , 1993 , 94, 147-52	4.3	5
132	Hippocampal benzodiazepine receptors in schizophrenia. <i>Journal of Neural Transmission</i> , 1993 , 93, 151-54.3		17
131	Neurochemical-clinical correlates in Huntington's disease--applications of brain banking techniques. <i>Journal of Neural Transmission Supplementum</i> , 1993 , 39, 207-14		7
130	The ratio of plasma phenylalanine to other large neutral amino acids is not a risk factor for tardive dyskinesia. <i>Journal of Psychopharmacology</i> , 1992 , 6, 278-80	4.6	1
129	An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. <i>Psychiatry Research - Neuroimaging</i> , 1992 , 45, 123-37	2.9	60
128	Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. <i>Neuroscience Letters</i> , 1992 , 144, 199-201	3.3	125
127	Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. <i>Schizophrenia Research</i> , 1992 , 7, 237-47	3.6	118
126	Neurochemical abnormalities in Huntington's disease: neurotoxic mechanisms and neurotransmitter changes. <i>Journal of the Neurological Sciences</i> , 1992 , 113, 230-3	3.2	4
125	Developments in the drug treatment of schizophrenia. <i>Trends in Pharmacological Sciences</i> , 1992 , 13, 116-21.2		130
124	Clozapine has sub-micromolar affinity for 5-HT _{1A} receptors in human brain tissue. <i>European Journal of Pharmacology</i> , 1992 , 221, 397-8	5.3	51
123	Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. <i>Cellular and Molecular Neurobiology</i> , 1992 , 12, 581-7	4.6	86
122	Studies on brain monoamine oxidase: a laboratory investigation in neurochemistry for first-year undergraduates. <i>Biochemical Education</i> , 1992 , 20, 55-56		1
121	Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study. <i>Journal of Neural Transmission</i> , 1992 , 87, 225-30	4.3	14
120	Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. Increased concentrations in hepatic encephalopathy. <i>Biomedical Applications</i> , 1991 , 565, 436-40		50
119	Neuroanatomical correlates of skin conductance orienting in normal humans: a magnetic resonance imaging study. <i>Psychophysiology</i> , 1991 , 28, 548-58	4.1	79

118	Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatography of stable o-phthalaldehyde-sulphite derivatives. <i>Journal of Neural Transmission</i> , 1991 , 86, 151-7	4.3	39
117	[3H]ditolylguanidine binding to human brain sigma sites is diminished after haloperidol treatment. <i>European Journal of Pharmacology</i> , 1991 , 194, 235-6	5.3	25
116	[3H]nipecotic acid binding to gamma-aminobutyric acid uptake sites in postmortem human brain. <i>Journal of Neurochemistry</i> , 1990 , 55, 165-8	6	12
115	Pallidal GABA and chorea in Huntington's disease. <i>Journal of Neural Transmission</i> , 1990 , 81, 241-6	4.3	8
114	Structural and functional characteristics of the corpus callosum in schizophrenics, psychiatric controls, and normal controls. A magnetic resonance imaging and neuropsychological evaluation. <i>Archives of General Psychiatry</i> , 1990 , 47, 1060-4		86
113	Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex. <i>Neuroscience Letters</i> , 1990 , 113, 95-100	3.3	28
112	No deficit of pallidal D2 dopamine receptors in Huntington's disease. <i>Journal of the Neurological Sciences</i> , 1990 , 100, 238-9	3.2	1
111	Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. <i>Biological Psychiatry</i> , 1990 , 27, 1038-44	7.9	183
110	Dopamine D2 -Receptors in Post-mortem Human Brains from Schizophrenic Patients 1990 , 507-513		
109	Alzheimer-like changes of cortical amino acid transmitters in elderly Down's syndrome. <i>Key Topics in Brain Research</i> , 1990 , 283-288		
108	Recommended minimum data to be collected in research studies on Alzheimer's disease. The MRC (UK) Alzheimer's Disease Workshop Steering Committee. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989 , 52, 693-700	5.5	44
107	[3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. <i>Journal of Neural Transmission</i> , 1989 , 77, 227-30	4.3	28
106	[3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. <i>Journal of Neural Transmission</i> , 1989 , 77, 231-6	4.3	230
105	3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. <i>Journal of Neural Transmission</i> , 1989 , 75, 1-10	4.3	178
104	Alzheimer-like cortical amino-acid changes in elderly Down's syndrome. <i>Journal of Neural Transmission Parkinsons Disease and Dementia Section</i> , 1989 , 1, 118-118		1
103	Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. <i>Journal of Neurochemistry</i> , 1989 , 52, 1781-6	6	346
102	Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. <i>Journal of Neurochemistry</i> , 1989 , 52, 515-20	6	1208
101	Increased brain 3-hydroxykynurenine in Huntington's disease. <i>Lancet, The</i> , 1989 , 2, 979-80	40	50

100	ALUMINIUM AND ALZHEIMER'S DISEASE. <i>Lancet, The</i> , 1989 , 333, 267-269	40	8
99	Tissue banking and EURAGE. <i>Journal of the Neurological Sciences</i> , 1989 , 93, 341-3	3.2	5
98	Reduced D-[3H]aspartate binding in Down's syndrome brains. <i>Brain Research</i> , 1989 , 484, 273-8	3.7	13
97	Serotonin concentrations and turnover in brains of depressed suicides. <i>Brain Research</i> , 1989 , 502, 332-40	3.7	66
96	Neuropeptides in Alzheimer's disease: a postmortem study. <i>Regulatory Peptides</i> , 1989 , 25, 123-30		45
95	Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata. <i>Neuroscience Letters</i> , 1989 , 100, 335-9	3.3	50
94	Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. <i>British Journal of Psychiatry</i> , 1989 , 155, 305-16	5.4	143
93	Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. <i>Journal of Neural Transmission</i> , 1988 , 74, 199-205	4.3	611
92	Brain quinolinic acid in Huntington's disease. <i>Journal of Neurochemistry</i> , 1988 , 50, 1959-60	6	100
91	Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. <i>Neuropharmacology</i> , 1988 , 27, 717-9	5.5	22
90	Glutamate dehydrogenase activity in amyotrophic lateral sclerosis. <i>Lancet, The</i> , 1988 , 2, 914	40	
89	Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. <i>Lancet, The</i> , 1988 , 1, 583-4	40	145
88	Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue. <i>Neuroscience Letters</i> , 1988 , 94, 224-7	3.3	47
87	Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. <i>Neuroscience</i> , 1988 , 25, 419-38	3.9	112
86	Post-mortem neurochemistry of schizophrenia. <i>Psychological Medicine</i> , 1988 , 18, 793-7	6.9	15
85	Status of the dopaminergic system in post-mortem brain in schizophrenia. <i>Psychopharmacology Bulletin</i> , 1988 , 24, 345-7	0.9	14
84	Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient. <i>European Archives of Psychiatry and Neurological Sciences</i> , 1988 , 238, 110-3		12
83	Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1987 , 50, 775-8	5.5	83

82	Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 1987 , 1, 256-62	2.5	123
81	Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes. <i>Archives of General Psychiatry</i> , 1987 , 44, 412-7		73
80	Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. <i>Neuroscience Letters</i> , 1987 , 78, 233-8	3.3	68
79	A correlative study on hippocampal cation shifts and amino acids and clinico-pathological data in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1987 , 8, 487-94	5.6	14
78	Maintenance of cortical somatostatin and monoamine levels in the rat does not require intact cholinergic innervation. <i>Brain Research</i> , 1987 , 406, 326-9	3.7	13
77	Neuropathology of Huntington's disease. <i>Trends in Neurosciences</i> , 1987 , 10, 404	13.3	2
76	Region-specific loss of glutamate innervation in Alzheimer's disease. <i>Neuroscience Letters</i> , 1987 , 73, 77-80	3.3	128
75	A disorder of cortical GABAergic innervation in Alzheimer's disease. <i>Neuroscience Letters</i> , 1987 , 73, 192-6	3.3	91
74	Dopamine receptor asymmetry in schizophrenia. <i>Lancet, The</i> , 1987 , 1, 979	4.0	30
73	HPLC analysis of somatostatin related peptides in putamen of Huntington's disease patients. <i>Journal of Neural Transmission</i> , 1987 , 69, 153-60	4.3	3
72	Human brain dopamine receptors in children and aging adults. <i>Synapse</i> , 1987 , 1, 399-404	2.4	351
71	Decreased brown adipose tissue thermogenic activity following a reduction in brain serotonin by intraventricular p-chlorophenylalanine. <i>Bioscience Reports</i> , 1987 , 7, 121-7	4.1	18
70	Postmortem Neurochemical Studies in Schizophrenia 1987 , 236-240		7
69	Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. <i>Neuropsychopharmacology</i> , 1987 , 1, 5-15	8.7	241
68	Subcellular pathology of human neurodegenerative disorders: Alzheimer-type dementia and Huntington's disease. <i>Journal of Neurochemistry</i> , 1986 , 47, 882-9	6	18
67	Dopamine D2 receptor density remains constant in treated Parkinson's disease. <i>Annals of Neurology</i> , 1986 , 19, 487-92	9.4	94
66	Striatal dopamine and homovanillic acid in Huntington's disease. <i>Journal of Neural Transmission</i> , 1986 , 65, 151-5	4.3	28
65	Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. <i>Neuroscience Letters</i> , 1986 , 67, 198-202	3.3	58

64	Lithium prophylaxis inhibits choline transport in post-mortem brain. <i>Lancet, The</i> , 1986 , 2, 458	40	8
63	Brain serotonin receptors in Huntington's disease. <i>Neurochemistry International</i> , 1986 , 9, 431-5	4.4	13
62	Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer's disease. <i>Neuroscience Letters</i> , 1986 , 68, 252-6	3.3	135
61	Regional distribution of a novel peptide (P7 of 1B236) immunoreactivity in the human central nervous system. <i>Neuroscience Letters</i> , 1986 , 67, 58-62	3.3	2
60	Amygdala Dopamine Asymmetry in Schizophrenia: Neurochemical Evidence for a Left Temporal Lobe Dysfunction 1986 , 285-291		2
59	Search for cytomegalovirus in postmortem brain tissue from patients with Huntington's chorea and other psychiatric disease by molecular hybridization using cloned DNA. <i>Journal of Neuropathology and Experimental Neurology</i> , 1985 , 44, 176-84	3.1	12
58	Ascending Systems in Alzheimer's Disease. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 1985 , 19, 198-212	3	1
57	Recombinant DNA studies on stored necropsy brain samples from patients with Huntington's chorea. <i>Journal of Clinical Pathology</i> , 1985 , 38, 1093-5	3.9	2
56	Alzheimer-like brain monoamine deficits in adults with Down's syndrome. <i>Lancet, The</i> , 1985 , 2, 1368-9	40	23
55	Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset. <i>Neuroscience Letters</i> , 1985 , 58, 123-6	3.3	19
54	Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. <i>Journal of the Neurological Sciences</i> , 1985 , 67, 161-71	3.2	112
53	[3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. <i>European Journal of Pharmacology</i> , 1985 , 114, 235-7	5.3	108
52	Neurochemical Studies in Human Postmortem Brain Tissue 1985 , 477-496		
51	Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. <i>JAMA - Journal of the American Medical Association</i> , 1985 , 254, 3067-9	27.4	22
50	Dopamine Function and Neuroleptics in Schizophrenia [Post-Mortem Studies of Human Brain Tissue 1985 , 209-213		
49	Receptors, Neuroleptics and Dopamine Concentrations in Schizophrenia [Postmortem Studies of Human Brain Tissue 1985 , 29-34		1
48	Brain Biochemistry in Schizophrenia: An Assessment 1985 , 35-43		3
47	Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. <i>JAMA - Journal of the American Medical Association</i> , 1985 , 254, 3067-3069	27.4	83

46	Early and late onset types of Alzheimer's disease 1984 , 288, 1612-1612		
45	Neurochemical characteristics of early and late onset types of Alzheimer's disease. <i>British Medical Journal</i> , 1984 , 288, 961-4		329
44	Bimodal distribution of dopamine receptor densities in brains of schizophrenics. <i>Science</i> , 1984 , 225, 728-313	313	316
43	Decreased proline endopeptidase activity in the basal ganglia in Huntington's disease. <i>Journal of Neurochemistry</i> , 1984 , 43, 878-80	6	11
42	Tetrahydrobiopterin metabolism in depression. <i>Lancet, The</i> , 1984 , 2, 163	40	35
41	Reduced binding of [3H]ketanserin to cortical 5-ht2 receptors in senile dementia of the Alzheimer type. <i>Neuroscience Letters</i> , 1984 , 44, 47-51	33	132
40	The pharmacology of Parkinson's disease: l-dopa and beyond. <i>Trends in Pharmacological Sciences</i> , 1984 , 5, 25-27	13.2	5
39	Noradrenaline and schizophrenia. <i>Trends in Pharmacological Sciences</i> , 1984 , 5, 138	13.2	
38	Phenylethylamine and Schizophrenia [Clinical and Pharmacological Results 1984 , 515-523		1
37	Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. <i>Neuroscience Letters</i> , 1983 , 39, 95-100	33	242
36	Neurotensin in the adrenal medulla. <i>Neuroscience Letters</i> , 1983 , 35, 155-60	33	43
35	Serotonin receptors in suicide victims. <i>Lancet, The</i> , 1983 , 2, 977	40	7
34	Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. <i>Psychiatry Research</i> , 1983 , 8, 243-50	9.9	46
33	Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors. <i>European Journal of Pharmacology</i> , 1983 , 89, 325-6	53	62
32	Tranlycypromine Isomers in Parkinson's Disease. <i>Modern Problems of Pharmacopsychiatry</i> , 1983 , 19, 154-161		2
31	Assessment of MAO inhibitors using postmortem human brain tissue: biochemical and therapeutic implications. <i>Modern Problems of Pharmacopsychiatry</i> , 1983 , 19, 255-9		1
30	Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls. <i>Archiv Fur Psychiatrie Und Nervenkrankheiten</i> , 1983 , 232, 463-71		24
29	Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. <i>Nature</i> , 1983 , 305, 527-9	50.4	364

28	Preliminary studies of human cortical 5-HT ₂ receptors and their involvement in schizophrenia and neuroleptic drug action. <i>Journal of Neural Transmission Supplementum</i> , 1983 , 18, 273-7		20
27	Thioridazine is not specific for limbic dopamine receptors. <i>Lancet, The</i> , 1982 , 2, 499-500	40	21
26	Parkinson's disease putamen: normal concentration of synaptic membrane marker antigens. <i>Journal of Neural Transmission</i> , 1982 , 54, 171-9	4.3	8
25	Dopamine receptors in post-mortem schizophrenic brains. <i>Lancet, The</i> , 1981 , 1, 1261	40	0
24	Tranlycypromine isomers in the treatment of Parkinson's disease. Biochemical effects. <i>International Pharmacopsychiatry</i> , 1981 , 16, 30-3		7
23	The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain. <i>Journal of Neural Transmission</i> , 1981 , 51, 107-11	4.3	8
22	Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic technique. <i>Biomedical Applications</i> , 1981 , 225, 179-84		12
21	Dopamine receptors and schizophrenia: the neuroleptic drug problem. <i>Neuropharmacology</i> , 1981 , 20, 1319-20	5.5	30
20	Tranlycypromine isomers and Parkinson's disease: new aspects of an old drug. <i>Journal of the Royal Society of Medicine</i> , 1981 , 74, 649-52	2.3	
19	TRACE AMINE DEFICIT IN DEPRESSIVE ILLNESS: THE PHENYLALANINE CONNEXION. <i>Acta Psychiatrica Scandinavica</i> , 1980 , 61, 29-39	6.5	14
18	The determination and distribution of 2-phenylethylamine in sheep brain. <i>Journal of Neurochemistry</i> , 1980 , 34, 1123-5	6	26
17	Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 1980 , 9, 98-9	3.8	11
16	Effects of tranlycypromine stereoisomers on monamine oxidation in man. <i>British Journal of Clinical Pharmacology</i> , 1980 , 9, 521-3	3.8	33
15	Dopamine receptors and schizophrenia: drug effect or illness. <i>Lancet, The</i> , 1980 , 2, 1251	40	31
14	Dopamine metabolism in human brain: effect of monoamine oxidase inhibition in vitro by (-)deprenyl and (+) and (-) tranlycypromine. <i>Journal of Neural Transmission Supplementum</i> , 1980 , 173-8		5
13	Deficient production of tyramine and octopamine in cases of depression. <i>Nature</i> , 1979 , 278, 357-8	50.4	87
12	Phenylethylamine - a role in mental illness?. <i>Trends in Neurosciences</i> , 1979 , 2, 265-268	13.3	18
11	2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings]. <i>Biochemical Society Transactions</i> , 1979 , 7, 143-5	5.1	19

10	Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. <i>Psychopharmacology</i> , 1978 , 57, 33-8	4.7	231
9	Gas chromatographic detection of N-methyl-2-phenylethylamine: a new component of human urine. <i>Biomedical Applications</i> , 1978 , 145, 137-40		8
8	Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. <i>Journal of Neural Transmission</i> , 1978 , 43, 271-7	4.3	123
7	Deprenyl is metabolized to methamphetamine and amphetamine in man. <i>British Journal of Clinical Pharmacology</i> , 1978 , 6, 542-4	3.8	242
6	The urinary excretion of 2-phenylethylamine in phenylketonuria. <i>Clinica Chimica Acta</i> , 1978 , 83, 33-9	6.2	16
5	The effect of urinary pH and flow rate on monoamine output. <i>Clinica Chimica Acta</i> , 1978 , 84, 225-31	6.2	5
4	Raised cerebrospinal fluid phenylacetic acid concentration: preliminary support for the phenylethylamine hypothesis of schizophrenia?. <i>Communications in Psychopharmacology</i> , 1978 , 2, 199-202		14
3	Does phenylethylamine cause schizophrenia?. <i>Lancet, The</i> , 1976 , 1, 70-1	4.0	112
2	A method for the estimation of 2-phenylethylamine in human urine by gas chromatography. <i>Clinica Chimica Acta</i> , 1976 , 70, 213-7	6.2	15
1	Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. <i>Journal of Psychopharmacology</i> ,	4.6	5